School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Animal Model Exp Med. 2023 Dec;6(6):598-608. doi: 10.1002/ame2.12351. Epub 2023 Oct 20.
In China, Rhizoma atractylodis macrocephalae-Paeonia lactiflora Pall (Biazhu-Baishao, BZBS) is a classic herb pair used to treat intestinal stress syndrome, ulcerative colitis and other diseases. However, the mechanism of BZBS in the treatment of functional constipation (FC) has been little studied and remains unclear. In this study, a behavioral investigation, colon tissue morphology, enzyme-linked immunosorbent assay (Elisa) and intestinal microflora analysis have been used to illuminate the potential mechanism of the effects of BZBS on FC in a rat model.
A FC rat model was constructed and BZBS was given as treatment. Observations and recordings were made of the fecal moisture content, the defecation time of the first black stool, and the rate of intestinal propulsion. Elisa was used to detect the expression levels of substance P (SP), vasoactive intestinal peptide (VIP), 5-hydroxytryptamine (5-HT) in the colon. To ascertain the composition of the microbial community, a high throughput 16S ribosomal RNA (16S rRNA) gene sequencing technique was employed.
Oral administration of BZBS significantly ameliorated several key excretion parameters, including the time to first black stool defecation, stool water content, and the propulsion rate in the small intestine in FC rats. It increased the expression of SP, VIP and 5-HT in the colon. 16S rRNA gene sequencing results showed that BZBS changed the microbial community structure, decreased the Bacteroidetes/Firmicutes ratio, increased the relative abundance of Blautia and Fusicatenibacter, and decreased the relative abundance of Ruminococcus and Roseburia.
BZBS effectively alleviates FC and improves dysbacteriosis.
在中国,白术-白芍(BZBS)是一种经典的药对,用于治疗肠应激综合征、溃疡性结肠炎等疾病。然而,BZBS 治疗功能性便秘(FC)的机制尚未得到充分研究,仍不清楚。本研究采用行为学观察、结肠组织形态学、酶联免疫吸附试验(ELISA)和肠道菌群分析,阐明 BZBS 对 FC 大鼠模型的潜在作用机制。
构建 FC 大鼠模型并给予 BZBS 治疗。观察并记录粪便含水量、首粒黑便排出时间和小肠推进率。ELISA 法检测结肠中 P 物质(SP)、血管活性肠肽(VIP)、5-羟色胺(5-HT)的表达水平。采用高通量 16S 核糖体 RNA(16S rRNA)基因测序技术检测微生物群落组成。
BZBS 口服给药可显著改善 FC 大鼠的几项关键排泄参数,包括首粒黑便排出时间、粪便含水量和小肠推进率。它增加了结肠中 SP、VIP 和 5-HT 的表达。16S rRNA 基因测序结果显示,BZBS 改变了微生物群落结构,降低了拟杆菌门/厚壁菌门的比例,增加了布劳特氏菌和 Fusicatenibacter 的相对丰度,降低了瘤胃球菌和罗斯伯里氏菌的相对丰度。
BZBS 有效缓解 FC 并改善肠道菌群失调。